We find that hydrochlorothiazide targets the sodium-chloride symporter pathway (e.g., SLC12A3) and spironolactone targets the mineralocorticoid receptor pathway (e.g., NR3C2), both in the hypertension disease module following by the Complementary Exposure category (Figs. 2b, 3b). This evidence concerns the gene NR3C2 and hypertensive disorder.